The array comparative genomic hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer.

During the test, scientists use a technique called array comparative genomic hybridisation to spot abnormalities in a genome.

This insight enables them to assess the likely risk of cancer developing and the potential location of a primary tumour. aCGH RGCC can help clinicians to understand more about a patient’s genes, giving them a powerful tool in the fight against cancer.